Abstract
Most cases of frontotemporal lobar degeneration (FTLD) are characterized by the abnormal accumulation of either the microtubule-associated protein tau or the transactive response DNA-binding protein with Mr 43 kDa, TDP-43 (FTLD-tau and FTLD-TDP, respectively). However, there remain ∼10% of cases, composed of a heterogenous collection of uncommon disorders, for which the molecular basis remains uncertain. In this review, we describe the characteristic genetic, clinical, and pathological features of the major tau/TDP-negative FTLD subtypes, with focus on recent advances in our understanding of their molecular basis. This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.
Similar content being viewed by others
References
Ahmad ST, Sweeney ST, Lee JA, Sweeney NT, Gao FB (2009) Genetic screen identifies serpin5 as a regulator of the toll pathway and CHMP2B toxicity associated with frontotemporal dementia. Proc Natl Acad Sci USA 106:12168–12173
Armstrong RA, Gearing M, Bigio EH et al (2010) The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease. Acta Neuropathol 121:219–228
Baumer D, Hilton D, Paine SML et al (2010) Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 75:611–618
Belly A, Bodon G, Blot B, Bouron A, Sadoul R, Goldberg Y (2010) CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines. J Cell Sci 123:2943–2954
Bigio EH, Lipton AM, White CL III, Dickson DW, Hirano A (2003) Frontotemporal and motor neurone degeneration with neurofilament inclusion bodies: additional evidence for overlap between FTD and ALS. Neuropathol Appl Neurobiol 29:239–253
Blair IP, Williams KL, Warraich ST et al (2010) FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 81:639–645
Broustal O, Camuzat A, Guillot-Noel L et al (2010) FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J Alzheimer's Dis 22:765–769
Brown J, Ashworth A, Gydesen S, Sorensen A, Rossor M, Hardy J et al (1995) Familial non-specific dementia maps to chromosome 3. Hum Mol Genet 4:1625–1628
Cairns NJ, Grossman M, Arnold SE et al (2004a) Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63:1376–1384
Cairns NJ, Uryu K, Bigio EH et al (2004b) α-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol 108:213–223
Cairns NJ, Zhukareva V, Uryu K et al (2004c) α-Internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol 164:2153–2161
Eskildsen SF, Ostergaard LR, Rodell AB et al (2009) Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriers. Neuroimage 45:713–721
Filimonenko M, Stuffers S, Raiborg C et al (2007) Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. J Cell Biol 179:485–500
Fujita K, Ito H, Nakano S, Kinoshita Y, Wate R, Kusaka H (2008) Immunohistochemical identification of messenger RNA-related proteins in basophilic inclusions of adult-onset atypical motor neuron disease. Acta Neuropathol 116:439–445
Fujita Y, Fujita S, Takatama M, Ikeda M, Okamoto K (2010) Numerous FUS-positive inclusions in an elderly woman with motor neuron disease. Neuropathology. doi:10.1111/j.1440-1789.2010.01146.x
Groen EJN, van Es MA, van Vught PWJ et al (2010) FUS mutation sin familial amyotrophic lateral sclerosis in the Netherlands. Arch Neurol 67:224–230
Gydesen S, Brown JM, Brun A et al (2002) Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology 59:1585–1594
Hewitt C, Kirby J, Highley R et al (2010) Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 67:455–461
Holm IE, Englund E, Mackenzie IR, Johannsen P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 66:884–891
Holm IE, Isaacs AM, Mackenzie IR (2009) Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Acta Neuropathol 118:719–720
Huang EJ, Zhang J, Geser F et al (2010) Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol 20:1069–1076
Isaacs AM, Johannsen P, Holm I, Nielsen JE (2011) Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res (in press)
Josephs KA, Holton JL, Rossor MN et al (2003) Neurofilament inclusion body disease: a new proteinopathy? Brain 126:2291–2303
Josephs KA, Uchikado H, McComb RD et al (2005) Extending the clinicopathological spectrum of neurofilament inclusion disease. Acta Neuropathol 109:427–432
Josephs KA, Lin WL, Ahmed Z, Stroh DA, Graff-Radford NR, Dickson DW (2008) Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol 116:159–167
Josephs KA, Whitwell JL, Parisi JE et al (2010) Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol 17:969–975
Katzmann DJ, Odorizzi G, Emr SD (2002) Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 3:893–905
Kobayashi Z, Tsuchiya K, Arai T et al (2010) Occurrence of basophilic inclusions and FUS-immunoreactive neuronal and glial inclusions in a case of familial amyotrophic lateral sclerosis. J Neurol Sci 293:6–11
Kwiatkowski TJ, Bosco DA, Leclerc AL et al (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208
Lee JA, Beigneux A, Ahmad ST, Young SG, Gao FB (2007) ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol 17:1561–1567
Lindquist SG, Braedgaard H, Svenstrup K, Isaacs AM, Nielsen JE (2008) Frontotemporal dementia linked to chromosome 3 (FTD-3)—current concepts and the detection of a previously unknown branch of the Danish FTD-3 family. Eur J Neurol 15:667–670
Mackenzie IR, Feldman H (2004) Neurofilament inclusion body disease with early onset frontotemporal dementia and primary lateral sclerosis. Clin Neuropathol 23:183–193
Mackenzie IR, Foti D, Woulfe J, Hurwitz TA (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282–1293
Mackenzie IR, Neumann M, Bigio EH et al (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117:15–18
Mackenzie IR, Neumann M, Bigio EH et al (2010a) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4
Mackenzie IRA, Rademakers R, Neumann M (2010b) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9:995–1007
Mackenzie IR, Munoz DG, Kusaka H et al (2011) Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol 121:207–218
Matsuoka T, Fujii N, Kondo A et al (2011) An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions. Neuropathology 31:71–76
Metcalf D, Isaacs AM (2010) The role of ESCRT proteins in fusion events involving lysosomes, endosomes and autophagosomes. Biochem Soc Trans 38:1469–1473
Molina-Porcel L, Llado A, Rey MJ et al (2008) Clinical and pathological heterogeneity of neuronal intermediate filament inclusion disease. Arch Neurol 65:272–275
Munoz DG, Neumann M, Kusaka H et al (2009) FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118:617–627
Munoz-Garcia D, Ludwin SK (1984) Classic and generalized variants of Pick’s disease: a clinicopathological, ultrastructural, and immunohistochemical comparative study. Ann Neurol 16:467–480
Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR (2009a) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931
Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR (2009b) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616
Neumann M, Tolnay M, Mackenzie IRA (2009c) The molecular basis of frontotemporal dementia. Exp Rev Mol Med 11:e23
Page T, Gitcho MA, Mosaheb M (2011) FUS immunogold labelling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy. J Mol Neurosci (this volume)
Rademakers R, Stewart H, DeJesus-Hernandez M et al (2010) FUS gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle Nerve 42:170–176
Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M (2008) TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol 116:147–157
Rohrer JD, Ahsan RL, Isaacs AM et al (2009) Presymptomatic generalized brain atrophy in frontotemporal dementia caused by CHMP2B mutation. Dement Geriatr Cogn Disord 27:182–186
Rohrer JD, Lashley T, Holton J (2011) The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry (in press)
Rusten TE, Stenmark H (2009) How do ESCRT proteins control autophagy? J Cell Sci 122:2179–2183
Seelaar H, Klijnsma KY, de Koning I et al (2010) Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J Neurol 257:747–753
Skibinski G, Parkinson NJ, Brown JM et al (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37:806–808
Suzuki N, Aoki M, Warita H et al (2010) FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusions. J Hum Genet 55:252–254
Tateishi T, Hokonohara T, Yamasaki R et al (2010) Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol 119:255–364
Urwin H, Ghazi-Noori S, Collinge J, Isaacs A (2009) The role of CHMP2B in frontotemporal dementia. Biochem Soc Trans 37:208–212
Urwin H, Authier A, Nielsen JE et al (2010a) Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Hum Mol Genet 19:2228–2238
Urwin H, Josephs KA, Rohrer JD et al (2010b) FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 120:33–41
van der Zee J, Urwin H, Engelborghs S et al (2008) CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet 17:313–322
Van Langenhove T, van der Zee J, Sleegers K et al (2010) Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 74:366–371
Vance C, Rogelj B, Hortobagyi T et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211
Yamamoto-Watanabe Y, Watanabe M, Okamoto K et al (2010) A Japanese ALS6 family with mutation R521C in the FUS/TLS gene: a clinical, pathological and genetic report. J Neurol Sci 296:59–63
Yan J, Deng HX, Siddique N et al (2010) Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 75:807–814
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mackenzie, I.R.A., Neumann, M., Cairns, N.J. et al. Novel Types of Frontotemporal Lobar Degeneration: Beyond Tau and TDP-43. J Mol Neurosci 45, 402–408 (2011). https://doi.org/10.1007/s12031-011-9551-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-011-9551-1